Alvotech In-Licenses Xolair Rival From BiosanaPharma

Alvotech has delivered on recent indications that it would look to use in-licensing deals to supplement its in-house biosimilars pipeline, striking a licensing deal with BiosanaPharma that will see the two companies collaborate on co-developing a rival to Novartis/Genentech’s Xolair (omalizumab) asthma and spontaneous urticaria treatment.

The exclusive global licensing agreement will see Alvotech and BiosanaPharma co-develop the AVT23 candidate – also referred to under the BiosanaPharma designation BP001 – for which BiosanaPharma has previously reported favorable Phase I trial results showing that “bioavailability, safety, tolerability and immunogenicity of BP001 are comparable to those of Xolair